FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949114920> ?p ?o ?g. }

• W2949114920 endingPage "1119" @default.
• W2949114920 startingPage "1119" @default.
• W2949114920 abstract "Abstract Background: A substantial percentage of patients transfused with blood products develop HLA allo-immunization. Although HLA-matched platelets are effective in treating thrombocytopenia for those with HLA antibodies, a significant proportion of patients lack HLA-compatible platelet products resulting in platelet transfusion refractoriness and life-threatening thrombocytopenia. We and others have shown that compliment activation leading to the destruction of platelets bound by HLA allo-antibodies may play a pathophysiologic role in platelet refractoriness. Eculizumab is a monoclonal antibody that binds and inhibits C5 complement, blocking both the classic and alternative pathways of complement. Here we investigated whether treatment with eculizumab could be used as a treatment in HLA allo-immunized patients to overcome platelet transfusion refractoriness. Methods: We conducted a phase II pilot trial (NCT02298933) of eculizumab treatment in 10 subjects who had 1) HLA allo-immunization (detectable HLA class I antibodies), 2) severe thrombocytopenia and 3) platelet transfusion refractoriness. Patients were treated with a single infusion of eculizumab at a dose of 1200mg. Platelet refractoriness was defined as a transfusion corrected platelet count increment (CCI) of 7500/uL at 10-60 minutes together with a CCI>5000/uL 18-24 hours post transfusion. Subjects were taken off study 14 days following eculizumab treatment. Responding patients who developed recurrent platelet refractoriness were eligible to re-enroll on study. All patients were required to receive meningococcal vaccination before eculizumab administration +/- antibiotic prophylaxis to cover N. meningitidis. Results: As of 4/2017, 11 Eculizumab infusions were administered to 10 HLA allo-immunized subjects (median age 39.5 years, range 20-71) with severe thrombocytopenia associated with platelet transfusion refractoriness. Patients had a diagnosis of SAA (n=4), refractory/relapsed AML (n=3); relapsed ALL (n=2) and high risk MDS (n=1). Total complement (CH50) was the most reliable measurement for complement inhibition; CH50 decreased to Remarkably, platelet refractoriness was overcome with eculizumab treatment in patients receiving HLA incompatible platelets; in 4 out of 5 cases where platelet refractoriness was overcome, the administered platelet product given immediately after eculizumab treatment expressed an HLA allele for which an HLA antibody had been detected in the patient's serum (Table 2) . Resolution of platelet refractoriness resulted in a clinically meaningful reduction in the requirement for platelet transfusions: the median number of platelet transfusion given 2 weeks before and 2 weeks after the eculizumab infusion in responding patients was 9 (range from 3 to 11) and 4 (range from 3 to 5) transfusions respectively. For the non-responders, the median number of platelet transfusions given 2 weeks before and 2 weeks after the eculizumab infusion was 8 (range from 5 to 10) and 9.5 (range from 5 to 15) transfusions respectively. Conclusions: Final data from this pilot trial suggest eculizumab has efficacy in overcoming HLA antibody-associated platelet transfusion refractoriness. Importantly, these data reveal that eculizumab has the ability to overcome platelet transfusion refractoriness in patients with broad HLA allo-immunization in situations where HLA compatible platelets are unavailable. This study establishes proof of principle of the therapeutic role that compliment inhibition can play in overcoming platelet transfusion refractoriness and lays the foundation for a larger multicenter trial to define the overall efficacy of this approach. Download : Download high-res image (231KB) Download : Download full-size image Disclosures No relevant conflicts of interest to declare." @default.
• W2949114920 created "2019-06-27" @default.
• W2949114920 creator A5012012199 @default.
• W2949114920 creator A5013999699 @default.
• W2949114920 creator A5020251665 @default.
• W2949114920 creator A5021539931 @default.
• W2949114920 creator A5035783745 @default.
• W2949114920 creator A5037993782 @default.
• W2949114920 creator A5050466936 @default.
• W2949114920 creator A5051959420 @default.
• W2949114920 creator A5059805179 @default.
• W2949114920 creator A5071433395 @default.
• W2949114920 creator A5076074380 @default.
• W2949114920 creator A5077082272 @default.
• W2949114920 creator A5077997844 @default.
• W2949114920 creator A5083445600 @default.
• W2949114920 creator A5083742882 @default.
• W2949114920 creator A5087705062 @default.
• W2949114920 creator A5090423342 @default.
• W2949114920 date "2017-12-07" @default.
• W2949114920 modified "2023-09-27" @default.
• W2949114920 title "Final Result of a Pilot Study Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Allo-Immunized Patients Receiving HLA Mismatched Platelets" @default.
• W2949114920 doi "https://doi.org/10.1182/blood.v130.suppl_1.1119.1119" @default.
• W2949114920 hasPublicationYear "2017" @default.
• W2949114920 type Work @default.
• W2949114920 sameAs 2949114920 @default.
• W2949114920 citedByCount "0" @default.
• W2949114920 crossrefType "journal-article" @default.
• W2949114920 hasAuthorship W2949114920A5012012199 @default.
• W2949114920 hasAuthorship W2949114920A5013999699 @default.
• W2949114920 hasAuthorship W2949114920A5020251665 @default.
• W2949114920 hasAuthorship W2949114920A5021539931 @default.
• W2949114920 hasAuthorship W2949114920A5035783745 @default.
• W2949114920 hasAuthorship W2949114920A5037993782 @default.
• W2949114920 hasAuthorship W2949114920A5050466936 @default.
• W2949114920 hasAuthorship W2949114920A5051959420 @default.
• W2949114920 hasAuthorship W2949114920A5059805179 @default.
• W2949114920 hasAuthorship W2949114920A5071433395 @default.
• W2949114920 hasAuthorship W2949114920A5076074380 @default.
• W2949114920 hasAuthorship W2949114920A5077082272 @default.
• W2949114920 hasAuthorship W2949114920A5077997844 @default.
• W2949114920 hasAuthorship W2949114920A5083445600 @default.
• W2949114920 hasAuthorship W2949114920A5083742882 @default.
• W2949114920 hasAuthorship W2949114920A5087705062 @default.
• W2949114920 hasAuthorship W2949114920A5090423342 @default.
• W2949114920 hasConcept C111684460 @default.
• W2949114920 hasConcept C121332964 @default.
• W2949114920 hasConcept C126322002 @default.
• W2949114920 hasConcept C142424586 @default.
• W2949114920 hasConcept C147483822 @default.
• W2949114920 hasConcept C159654299 @default.
• W2949114920 hasConcept C188280979 @default.
• W2949114920 hasConcept C203014093 @default.
• W2949114920 hasConcept C2776689292 @default.
• W2949114920 hasConcept C2777991916 @default.
• W2949114920 hasConcept C70616116 @default.
• W2949114920 hasConcept C71924100 @default.
• W2949114920 hasConcept C87355193 @default.
• W2949114920 hasConcept C89560881 @default.
• W2949114920 hasConcept C90924648 @default.
• W2949114920 hasConceptScore W2949114920C111684460 @default.
• W2949114920 hasConceptScore W2949114920C121332964 @default.
• W2949114920 hasConceptScore W2949114920C126322002 @default.
• W2949114920 hasConceptScore W2949114920C142424586 @default.
• W2949114920 hasConceptScore W2949114920C147483822 @default.
• W2949114920 hasConceptScore W2949114920C159654299 @default.
• W2949114920 hasConceptScore W2949114920C188280979 @default.
• W2949114920 hasConceptScore W2949114920C203014093 @default.
• W2949114920 hasConceptScore W2949114920C2776689292 @default.
• W2949114920 hasConceptScore W2949114920C2777991916 @default.
• W2949114920 hasConceptScore W2949114920C70616116 @default.
• W2949114920 hasConceptScore W2949114920C71924100 @default.
• W2949114920 hasConceptScore W2949114920C87355193 @default.
• W2949114920 hasConceptScore W2949114920C89560881 @default.
• W2949114920 hasConceptScore W2949114920C90924648 @default.
• W2949114920 hasLocation W29491149201 @default.
• W2949114920 hasOpenAccess W2949114920 @default.
• W2949114920 hasPrimaryLocation W29491149201 @default.
• W2949114920 hasRelatedWork W174562405 @default.
• W2949114920 hasRelatedWork W1985809909 @default.
• W2949114920 hasRelatedWork W1994810794 @default.
• W2949114920 hasRelatedWork W2103274960 @default.
• W2949114920 hasRelatedWork W2149964399 @default.
• W2949114920 hasRelatedWork W2321634559 @default.
• W2949114920 hasRelatedWork W2385917911 @default.
• W2949114920 hasRelatedWork W2502923083 @default.
• W2949114920 hasRelatedWork W2518075208 @default.
• W2949114920 hasRelatedWork W2565114624 @default.
• W2949114920 hasRelatedWork W2606258947 @default.
• W2949114920 hasRelatedWork W2772200349 @default.
• W2949114920 hasRelatedWork W2783193454 @default.
• W2949114920 hasRelatedWork W2784733195 @default.
• W2949114920 hasRelatedWork W2935941799 @default.
• W2949114920 hasRelatedWork W2999487750 @default.
• W2949114920 hasRelatedWork W3008117228 @default.
• W2949114920 hasRelatedWork W3034436291 @default.
• W2949114920 hasRelatedWork W3133925731 @default.
• W2949114920 hasRelatedWork W3169486710 @default.

• next